Bioxytran (BIXT) Stock Chart & Stock Price History $0.08 +0.00 (+4.75%) As of 08/22/2025 03:46 PM Eastern Add Compare Share Share Chart Stock AnalysisChartEarningsHeadlinesSEC FilingsShort InterestBuy This Stock Bioxytran Stock Price Performance The Bioxytran (BIXT) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 5.74%, with a year-to-date return of -6.79%. In the past month, the stock has decreased 8.81%, reflecting recent market activity. As of the latest close, Bioxytran traded at $0.08 with a market cap of $7.46 million and volume of 312,829 shares. Receive BIXT Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Bioxytran and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+7.85%1 Month Performance-8.81%3 Month Performance-44.72%Year-To-Date Performance-6.79%1 Year Performance-5.74% BIXT Stock Chart for Sunday, August, 24, 2025 BIXT Chart by TradingView Bioxytran Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization08/22/2025$0.08$0.08+4.75%$0.08$0.08312,829 shs$7.46 million08/21/2025$0.08$0.08+5.26%$0.08$0.0812,125 shs$7.12 million08/20/2025$0.08$0.08-2.19%$0.08$0.0844,213 shs$6.76 million08/19/2025$0.08$0.08-3.60%$0.08$0.0853,600 shs$6.92 million08/18/2025$0.08$0.08+0.75%$0.08$0.08161,922 shs$7.17 million08/15/2025$0.08$0.08-4.99%$0.08$0.07169,735 shs$7.12 million08/14/2025$0.08$0.08+7.40%$0.08$0.07291,275 shs$7.49 million08/13/2025$0.08$0.08+1.03%$0.08$0.08239,217 shs$6.98 million08/12/2025$0.08$0.08-8.38%$0.09$0.08117,787 shs$6.91 million08/11/2025$0.08$0.08+5.87%$0.09$0.0867,521 shs$7.54 million Get the Latest News and Ratings for BIXT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Bioxytran and its competitors with MarketBeat's FREE daily newsletter. 08/08/2025$0.08$0.08+0.13%$0.09$0.0894,913 shs$7.12 million08/07/2025$0.08$0.08-2.44%$0.08$0.0827,800 shs$7.11 million08/06/2025$0.08$0.08-0.12%$0.08$0.0847,514 shs$7.29 million08/05/2025$0.09$0.08-3.53%$0.09$0.088,900 shs$7.30 million08/04/2025$0.09$0.09-5.56%$0.09$0.08110,713 shs$7.56 million08/01/2025$0.09$0.09-4.26%$0.10$0.0937,250 shs$8.01 million07/31/2025$0.09$0.09+3.98%$0.10$0.0882,613 shs$8.37 million07/30/2025$0.09$0.09+3.91%$0.09$0.0832,003 shs$8.05 million07/29/2025$0.08$0.09+5.58%$0.09$0.08106,615 shs$7.74 million07/28/2025$0.09$0.08-4.19%$0.09$0.08145,402 shs$7.33 million07/25/2025$0.09$0.09-6.42%$0.09$0.0837,301 shs$7.65 million07/24/2025$0.09$0.09+2.11%$0.09$0.0896,676 shs$8.18 million07/23/2025$0.09$0.09+5.63%$0.09$0.0936,406 shs$8.01 million Related Companies Generation Bio Stock Chart Rein Therapeutics Stock Chart OnKure Therapeutics Stock Chart Dyadic International Stock Chart Biodexa Pharmaceuticals Stock Chart JATT Acquisition Stock Chart Tenax Therapeutics Stock Chart NanoViricides Stock Chart FibroBiologics Stock Chart Natural Alternatives International Stock Chart Receive BIXT Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Bioxytran and its competitors with MarketBeat's FREE daily newsletter. This page (OTCMKTS:BIXT) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredTrump’s SHOCKING Plan to Create MASSIVE Wealth for AmericansJames Altucher says Donald Trump just made a move so surprising, it could go down as the most lucrative presid...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioxytran, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioxytran With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access